Evidence map›Paper›PMID 36569962›Full record

ArticleFrontiers in chemistry2022

Design and synthesis of ERα agonists: Effectively reduce lipid accumulation.

Jinfei Yang, Weiwei Yao, Huihui Yang, Yajing Shen, Yuanyuan Zhang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jinfei YangSchool of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao, China.
Weiwei YaoSchool of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao, China.
Huihui YangSchool of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao, China.
Yajing ShenSchool of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao, China.
Yuanyuan ZhangWest China School of Pharmacy, Sichuan University, Chengdu, China.
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, the incidence of non-alcoholic fatty liver disease (NAFLD) has been increasing worldwide. Hepatic lipid deposition is a major feature of NAFLD, and insulin resistance is one of the most important causes of lipid deposition. Insulin resistance results in the disruption of lipid metabolism homeostasis characterized by increased lipogenesis and decreased lipolysis. Estrogen receptor

Indexed as

agonistsERαlipid accumulationliver diseaseNAFLD

Identifiers

PMID36569962
PMCPMC9772986
OpenAlexW4311858216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.